The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells
| العنوان: | The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells |
|---|---|
| المؤلفون: | Michael O׳Dwyer, Eva Szegezdi, Denis V. Baev, Janusz Krawczyk |
| المصدر: | Leukemia Research Reports, Vol 3, Iss 2, Pp 79-82 (2014) Leukemia Research Reports |
| بيانات النشر: | Elsevier, 2014. |
| سنة النشر: | 2014 |
| مصطلحات موضوعية: | Acute myeloid leukemia, ABT-737, business.industry, CD34, Myeloid leukemia, Case Report, Hematology, Pharmacology, Putative leukemic stem cells, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Minimal residual disease, lcsh:RC254-282, 3. Good health, Haematopoiesis, Oncology, Cytarabine, Medicine, Cytotoxic T cell, Progenitor cell, Stem cell, business, medicine.drug, CD34+/CD38−, BH3-mimetic |
| الوصف: | The anti-apoptotic proteins Bcl-XL and Bcl-2 are abundantly expressed in hematopoietic stem cells and/or progenitor cells. Furthermore, leukemic cells expressing these proteins are enriched in minimal residual disease cell populations. This prompted us to test the BH3-mimetic compound ABT-737 for its ability to eradicate putative leukemic stem cells. ABT-737 demonstrated potent cytotoxic effects in all patient samples tested. The efficacy of ABT-737 against AML blasts and the primitive CD34+/CD38− population was equal and independent of sensitivity to cytarabine/daunorubicin. These results, together with previously reported synergistic effects of ABT-737 with chemotherapeutics make BH3-mimetics promising candidates for future AML treatment regimens. Highlights • ABT-737 potently kills AML blast cells. • ABT-737 has a cytotoxic effect against both bone marrow-derived AML blasts and putative Leukemic Stem cells (pLSCs). • ABT-737 has an equally high cytotoxic efficacy in disseminated AML putative Leukemic Stem cells (pLSCs). |
| اللغة: | English |
| تدمد: | 2213-0489 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b33d869bd4f179d9244c50488c4533fTest http://www.sciencedirect.com/science/article/pii/S2213048914000120Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....3b33d869bd4f179d9244c50488c4533f |
| قاعدة البيانات: | OpenAIRE |
| ResultId |
1 |
|---|---|
| Header |
edsair OpenAIRE edsair.doi.dedup.....3b33d869bd4f179d9244c50488c4533f 807 3 unknown 806.518249511719 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....3b33d869bd4f179d9244c50488c4533f&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
|
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Michael+O׳Dwyer%22">Michael O׳Dwyer</searchLink><br /><searchLink fieldCode="AR" term="%22Eva+Szegezdi%22">Eva Szegezdi</searchLink><br /><searchLink fieldCode="AR" term="%22Denis+V%2E+Baev%22">Denis V. Baev</searchLink><br /><searchLink fieldCode="AR" term="%22Janusz+Krawczyk%22">Janusz Krawczyk</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Leukemia Research Reports, Vol 3, Iss 2, Pp 79-82 (2014)<br />Leukemia Research Reports ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Elsevier, 2014. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2014 ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Acute+myeloid+leukemia%22">Acute myeloid leukemia</searchLink><br /><searchLink fieldCode="DE" term="%22ABT-737%22">ABT-737</searchLink><br /><searchLink fieldCode="DE" term="%22business%2Eindustry%22">business.industry</searchLink><br /><searchLink fieldCode="DE" term="%22CD34%22">CD34</searchLink><br /><searchLink fieldCode="DE" term="%22Myeloid+leukemia%22">Myeloid leukemia</searchLink><br /><searchLink fieldCode="DE" term="%22Case+Report%22">Case Report</searchLink><br /><searchLink fieldCode="DE" term="%22Hematology%22">Hematology</searchLink><br /><searchLink fieldCode="DE" term="%22Pharmacology%22">Pharmacology</searchLink><br /><searchLink fieldCode="DE" term="%22Putative+leukemic+stem+cells%22">Putative leukemic stem cells</searchLink><br /><searchLink fieldCode="DE" term="%22lcsh%3ANeoplasms%2E+Tumors%2E+Oncology%2E+Including+cancer+and+carcinogens%22">lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens</searchLink><br /><searchLink fieldCode="DE" term="%22Minimal+residual+disease%22">Minimal residual disease</searchLink><br /><searchLink fieldCode="DE" term="%22lcsh%3ARC254-282%22">lcsh:RC254-282</searchLink><br /><searchLink fieldCode="DE" term="%223%2E+Good+health%22">3. Good health</searchLink><br /><searchLink fieldCode="DE" term="%22Haematopoiesis%22">Haematopoiesis</searchLink><br /><searchLink fieldCode="DE" term="%22Oncology%22">Oncology</searchLink><br /><searchLink fieldCode="DE" term="%22Cytarabine%22">Cytarabine</searchLink><br /><searchLink fieldCode="DE" term="%22Medicine%22">Medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Cytotoxic+T+cell%22">Cytotoxic T cell</searchLink><br /><searchLink fieldCode="DE" term="%22Progenitor+cell%22">Progenitor cell</searchLink><br /><searchLink fieldCode="DE" term="%22Stem+cell%22">Stem cell</searchLink><br /><searchLink fieldCode="DE" term="%22business%22">business</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Edrug%22">medicine.drug</searchLink><br /><searchLink fieldCode="DE" term="%22CD34%2B%2FCD38−%22">CD34+/CD38−</searchLink><br /><searchLink fieldCode="DE" term="%22BH3-mimetic%22">BH3-mimetic</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => The anti-apoptotic proteins Bcl-XL and Bcl-2 are abundantly expressed in hematopoietic stem cells and/or progenitor cells. Furthermore, leukemic cells expressing these proteins are enriched in minimal residual disease cell populations. This prompted us to test the BH3-mimetic compound ABT-737 for its ability to eradicate putative leukemic stem cells. ABT-737 demonstrated potent cytotoxic effects in all patient samples tested. The efficacy of ABT-737 against AML blasts and the primitive CD34+/CD38− population was equal and independent of sensitivity to cytarabine/daunorubicin. These results, together with previously reported synergistic effects of ABT-737 with chemotherapeutics make BH3-mimetics promising candidates for future AML treatment regimens.<br />Highlights • ABT-737 potently kills AML blast cells. • ABT-737 has a cytotoxic effect against both bone marrow-derived AML blasts and putative Leukemic Stem cells (pLSCs). • ABT-737 has an equally high cytotoxic efficacy in disseminated AML putative Leukemic Stem cells (pLSCs). ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 2213-0489 ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b33d869bd4f179d9244c50488c4533f" linkWindow="_blank">https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b33d869bd4f179d9244c50488c4533f</link><br /><link linkTarget="URL" linkTerm="http://www.sciencedirect.com/science/article/pii/S2213048914000120" linkWindow="_blank">http://www.sciencedirect.com/science/article/pii/S2213048914000120</link> ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => OPEN ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsair.doi.dedup.....3b33d869bd4f179d9244c50488c4533f ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 4
[StartPage] => 79
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => Acute myeloid leukemia
[Type] => general
)
[1] => Array
(
[SubjectFull] => ABT-737
[Type] => general
)
[2] => Array
(
[SubjectFull] => business.industry
[Type] => general
)
[3] => Array
(
[SubjectFull] => CD34
[Type] => general
)
[4] => Array
(
[SubjectFull] => Myeloid leukemia
[Type] => general
)
[5] => Array
(
[SubjectFull] => Case Report
[Type] => general
)
[6] => Array
(
[SubjectFull] => Hematology
[Type] => general
)
[7] => Array
(
[SubjectFull] => Pharmacology
[Type] => general
)
[8] => Array
(
[SubjectFull] => Putative leukemic stem cells
[Type] => general
)
[9] => Array
(
[SubjectFull] => lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
[Type] => general
)
[10] => Array
(
[SubjectFull] => Minimal residual disease
[Type] => general
)
[11] => Array
(
[SubjectFull] => lcsh:RC254-282
[Type] => general
)
[12] => Array
(
[SubjectFull] => 3. Good health
[Type] => general
)
[13] => Array
(
[SubjectFull] => Haematopoiesis
[Type] => general
)
[14] => Array
(
[SubjectFull] => Oncology
[Type] => general
)
[15] => Array
(
[SubjectFull] => Cytarabine
[Type] => general
)
[16] => Array
(
[SubjectFull] => Medicine
[Type] => general
)
[17] => Array
(
[SubjectFull] => Cytotoxic T cell
[Type] => general
)
[18] => Array
(
[SubjectFull] => Progenitor cell
[Type] => general
)
[19] => Array
(
[SubjectFull] => Stem cell
[Type] => general
)
[20] => Array
(
[SubjectFull] => business
[Type] => general
)
[21] => Array
(
[SubjectFull] => medicine.drug
[Type] => general
)
[22] => Array
(
[SubjectFull] => CD34+/CD38−
[Type] => general
)
[23] => Array
(
[SubjectFull] => BH3-mimetic
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Michael O׳Dwyer
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Eva Szegezdi
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Denis V. Baev
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Janusz Krawczyk
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 01
[Type] => published
[Y] => 2014
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 22130489
)
[1] => Array
(
[Type] => issn-locals
[Value] => edsair
)
[2] => Array
(
[Type] => issn-locals
[Value] => edsairFT
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 3
)
[1] => Array
(
[Type] => issue
[Value] => 2
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Leukemia Research Reports
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |